MX2020012978A - Sales de sepiapterina farmacéuticamente aceptables. - Google Patents
Sales de sepiapterina farmacéuticamente aceptables.Info
- Publication number
- MX2020012978A MX2020012978A MX2020012978A MX2020012978A MX2020012978A MX 2020012978 A MX2020012978 A MX 2020012978A MX 2020012978 A MX2020012978 A MX 2020012978A MX 2020012978 A MX2020012978 A MX 2020012978A MX 2020012978 A MX2020012978 A MX 2020012978A
- Authority
- MX
- Mexico
- Prior art keywords
- sepiapterin
- salts
- relates
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- VPVOXUSPXFPWBN-VKHMYHEASA-N sepiapterin Chemical class N1C(N)=NC(=O)C2=C1NCC(C(=O)[C@@H](O)C)=N2 VPVOXUSPXFPWBN-VKHMYHEASA-N 0.000 title abstract 5
- VPVOXUSPXFPWBN-UHFFFAOYSA-N L-sepiapterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(=O)C(O)C)=N2 VPVOXUSPXFPWBN-UHFFFAOYSA-N 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 229940126478 sepiapterin Drugs 0.000 title abstract 4
- 239000013078 crystal Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 abstract 1
- 229960004617 sapropterin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/06—Glycolic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678025P | 2018-05-30 | 2018-05-30 | |
| US201862726612P | 2018-09-04 | 2018-09-04 | |
| US201962822336P | 2019-03-22 | 2019-03-22 | |
| GC201937661 | 2019-05-28 | ||
| PCT/US2019/034505 WO2019232120A1 (en) | 2018-05-30 | 2019-05-30 | Pharmaceutically acceptable salts of sepiapterin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012978A true MX2020012978A (es) | 2021-04-28 |
Family
ID=68699017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012978A MX2020012978A (es) | 2018-05-30 | 2019-05-30 | Sales de sepiapterina farmacéuticamente aceptables. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12637465B2 (enExample) |
| EP (1) | EP3807279B1 (enExample) |
| JP (2) | JP7778477B2 (enExample) |
| KR (1) | KR20210038848A (enExample) |
| CN (1) | CN112543758A (enExample) |
| AU (2) | AU2019277372B2 (enExample) |
| BR (1) | BR112020024332A2 (enExample) |
| CA (1) | CA3102070A1 (enExample) |
| CL (1) | CL2020003101A1 (enExample) |
| CO (1) | CO2020016582A2 (enExample) |
| IL (1) | IL279101A (enExample) |
| MX (1) | MX2020012978A (enExample) |
| WO (1) | WO2019232120A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| WO2018102315A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CA3102105A1 (en) * | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7778477B2 (ja) * | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| JP7502197B2 (ja) | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| CA3165636A1 (en) | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| CN114621198B (zh) * | 2020-12-11 | 2025-01-21 | 北京夏禾科技有限公司 | 有机电致发光材料及其器件 |
| US12691119B2 (en) | 2021-02-09 | 2026-07-28 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| IL305037A (en) | 2021-02-09 | 2023-10-01 | Ptc Therapeutics Mp Inc | Methods of treating glioblastomas with spiafatrin |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US5753656A (en) * | 1994-08-05 | 1998-05-19 | Suntory Limited | Method for treating spinocerebellar degeneration |
| WO1997007236A1 (en) | 1995-08-18 | 1997-02-27 | Landry Donald W | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| JP2007509909A (ja) | 2003-10-31 | 2007-04-19 | アルタナ ファルマ アクチエンゲゼルシャフト | 呼吸器疾患の治療のためのｂｈ４の使用 |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| CA2545968C (en) | 2003-11-17 | 2010-03-09 | Merck Eprova Ag | Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| PT3138566T (pt) | 2003-11-17 | 2022-02-02 | Biomarin Pharm Inc | Tratamento de fenilcetonúria com bh4 |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| US20100130500A1 (en) | 2004-12-08 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2006118322A1 (en) | 2005-04-28 | 2006-11-09 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| KR20160065998A (ko) | 2007-04-11 | 2016-06-09 | 바이오마린 파머수티컬 인크. | 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법 |
| LT2262790T (lt) | 2008-03-10 | 2017-08-25 | Takeda Pharmaceutical Company Limited | Benzimidazolo junginio kristalas |
| WO2010017570A2 (de) | 2008-08-12 | 2010-02-18 | Orpha Swiss Gmbh | Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| IN2012DN01453A (enExample) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| JP5066756B2 (ja) * | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CA2828685C (en) | 2011-03-01 | 2018-05-29 | Rubicon Research Private Limited | Stable compositions of tetrahydrobiopterin |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| JP6084967B2 (ja) | 2012-05-07 | 2017-02-22 | 白鳥製薬株式会社 | セピアプテリン及びテトラヒドロラクトイルプテリンの製造法 |
| WO2017218421A1 (en) * | 2016-06-13 | 2017-12-21 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| WO2018019931A1 (en) | 2016-07-29 | 2018-02-01 | Dipharma S.A. | Pharmaceutical composition kit comprising sapropterin dihydrochloride |
| WO2018102315A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CA3102105A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7778477B2 (ja) * | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| JP7502197B2 (ja) | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
-
2019
- 2019-05-30 JP JP2020566701A patent/JP7778477B2/ja active Active
- 2019-05-30 US US17/059,887 patent/US12637465B2/en active Active
- 2019-05-30 EP EP19811127.0A patent/EP3807279B1/en active Active
- 2019-05-30 AU AU2019277372A patent/AU2019277372B2/en active Active
- 2019-05-30 KR KR1020207037815A patent/KR20210038848A/ko not_active Ceased
- 2019-05-30 CN CN201980050845.2A patent/CN112543758A/zh active Pending
- 2019-05-30 CA CA3102070A patent/CA3102070A1/en active Pending
- 2019-05-30 BR BR112020024332-9A patent/BR112020024332A2/pt unknown
- 2019-05-30 MX MX2020012978A patent/MX2020012978A/es unknown
- 2019-05-30 WO PCT/US2019/034505 patent/WO2019232120A1/en not_active Ceased
-
2020
- 2020-11-27 CL CL2020003101A patent/CL2020003101A1/es unknown
- 2020-11-30 IL IL279101A patent/IL279101A/en unknown
- 2020-12-29 CO CONC2020/0016582A patent/CO2020016582A2/es unknown
-
2024
- 2024-02-29 JP JP2024030700A patent/JP7841008B2/ja active Active
-
2025
- 2025-02-13 AU AU2025201002A patent/AU2025201002A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020003101A1 (es) | 2021-05-14 |
| AU2019277372B2 (en) | 2024-12-19 |
| JP2024063143A (ja) | 2024-05-10 |
| JP7841008B2 (ja) | 2026-04-06 |
| JP2021527031A (ja) | 2021-10-11 |
| EP3807279A1 (en) | 2021-04-21 |
| EP3807279B1 (en) | 2025-12-31 |
| US20210269443A1 (en) | 2021-09-02 |
| WO2019232120A1 (en) | 2019-12-05 |
| KR20210038848A (ko) | 2021-04-08 |
| JP7778477B2 (ja) | 2025-12-02 |
| CO2020016582A2 (es) | 2021-04-08 |
| AU2025201002A1 (en) | 2025-03-06 |
| EP3807279A4 (en) | 2022-04-06 |
| CN112543758A (zh) | 2021-03-23 |
| IL279101A (en) | 2021-01-31 |
| CA3102070A1 (en) | 2019-12-05 |
| BR112020024332A2 (pt) | 2021-02-23 |
| US12637465B2 (en) | 2026-05-26 |
| AU2019277372A1 (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020016582A2 (es) | Sales de sepiapterina farmacéuticamente aceptables | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX383856B (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| TN2017000119A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| TN2016000268A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2. | |
| MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX386256B (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| MY183536A (en) | Pharmaceutical compositions comprising azd9291 | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| JOP20200100A1 (ar) | مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 | |
| SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
| MY179783A (en) | Substituted bicyclic compounds | |
| MX380037B (es) | Antagonistas novedosos 5-ht2 | |
| WO2018160178A8 (en) | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof | |
| TN2018000214A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. |